Durect CORP 8-K filings

DURECT Corporation has completed its acquisition by Bausch Health Americas, Inc. for $1.75 per share in cash plus a contingent value right.

DURECT Corporation announced its second quarter 2025 financial results and provided an update on its proposed acquisition by Bausch Health, which includes an upfront cash payment of $1.75 per share and potential milestone payments up to $350 million.

DURECT Corporation and Bausch Health Americas, Inc. amended their merger agreement to extend the tender offer commencement date by one day to August 12, 2025.

Bausch Health Americas, Inc. will acquire DURECT Corporation for $1.75 per share in cash plus one non-tradeable contingent value right per share, potentially adding up to $350 million in milestone payments related to larsucosterol net sales.

DURECT Corporation has received an additional 180-day grace period from Nasdaq until January 5, 2026, to regain compliance with the $1.00 minimum bid price requirement, with a potential reverse stock split anticipated if necessary.

DURECT Corporation reports its Q1 2025 financial results, highlights the publication of the Phase 2b AHFIRM trial results, and announces plans for a registrational Phase 3 trial of larsucosterol for alcohol-associated hepatitis, contingent on securing funding.

DURECT Corporation reports positive Phase 2b trial results for Larsucosterol in alcohol-associated hepatitis (AH) and provides a business update, including the sale of the ALZET product line.

Terrence F. Blaschke resigns from DURECT Corporation's Board of Directors and Nominating Committee, effective immediately, with no reported disagreements.

DURECT Corporation's larsucosterol shows promise in treating alcohol-associated hepatitis, with Phase 2b results published in NEJM Evidence and a Phase 3 trial planned.

DURECT Corporation received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.

DURECT Corporation has finalized the sale of its ALZET product line to Lafayette Instruments Co., providing pro forma financial information reflecting the transaction's impact.

DURECT Corporation has sold its ALZET product line to Lafayette Instrument Co. for $17.5 million, using the proceeds to pay off its remaining debt with Oxford Finance LLC.

DURECT Corporation reported its third quarter 2024 financial results and provided an update on its business, including plans to initiate a Phase 3 trial for larsucosterol.

DURECT Corporation's stockholders approved an amendment to the 2000 Stock Plan, increasing available shares by 2 million and extending the plan's term, along with an increase in authorized common stock shares.

DURECT Corporation has finalized the design for its Phase 3 trial of larsucosterol for severe alcohol-associated hepatitis, following a Type B meeting with the FDA under Breakthrough Therapy designation.

DURECT Corporation has finalized the design for its Phase 3 trial of larsucosterol for severe alcohol-associated hepatitis, following a Type B meeting with the FDA under Breakthrough Therapy designation.

DURECT Corporation reported its second quarter 2024 financial results, highlighted by a Breakthrough Therapy Designation from the FDA for its drug candidate, larsucosterol, in treating alcohol-associated hepatitis.

DURECT Corporation's board of directors approved a grant of 275,000 restricted stock units to Chief Financial Officer Timothy M. Papp.

DURECT Corporation has dismissed Ernst & Young as their independent auditor and appointed WithumSmith+Brown, effective June 28, 2024.

DURECT Corporation announced that the FDA has granted Breakthrough Therapy designation to larsucosterol for the treatment of severe alcohol-associated hepatitis.

DURECT Corporation reported its first quarter 2024 financial results and announced that FDA feedback supports a single pivotal Phase 3 trial for larsucosterol in alcohol-associated hepatitis.

DURECT Corporation will present Phase 2b AHFIRM trial data for larsucosterol in treating severe alcohol-associated hepatitis at the EASL Congress in June 2024.

DURECT Corporation reported its fourth quarter and full year 2023 financial results, highlighting progress with its lead drug candidate, larsucosterol, and a new co-marketing agreement.

DURECT Corporation has regained compliance with Nasdaq's minimum bid price requirement after its stock price closed at or above $1.00 for 10 consecutive business days.

DURECT Corporation and Charles River Laboratories have entered into a co-marketing and collaboration agreement for the ALZET Osmotic Pumps product line in the U.S. and Canada.